EP1811838A4 - Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death - Google Patents

Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death

Info

Publication number
EP1811838A4
EP1811838A4 EP05848068A EP05848068A EP1811838A4 EP 1811838 A4 EP1811838 A4 EP 1811838A4 EP 05848068 A EP05848068 A EP 05848068A EP 05848068 A EP05848068 A EP 05848068A EP 1811838 A4 EP1811838 A4 EP 1811838A4
Authority
EP
European Patent Office
Prior art keywords
cell death
tweak
cerebral edema
nervous system
central nervous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05848068A
Other languages
German (de)
French (fr)
Other versions
EP1811838A2 (en
Inventor
Jeffrey A Winkles
Manuel S Yepes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Maryland at Baltimore
Original Assignee
University of Maryland at Baltimore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Maryland at Baltimore filed Critical University of Maryland at Baltimore
Publication of EP1811838A2 publication Critical patent/EP1811838A2/en
Publication of EP1811838A4 publication Critical patent/EP1811838A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to compositions and methods for treating cerebral edema and cell death in neurological conditions characterized by disruption of the architecture of the neurovascular unit with increase in the permeability of the NVU, particularly for treating stroke. One aspect of the present invention relates to a composition comprising an agent that interferes with a TWEAK-mediated signaling pathway. Another aspect of the present invention relates to a method of using a composition which comprises an agent that inhibits Fn14 activity or Fn14 expression for the prevention and/or treatment of cerebral edema and cell death occurring in certain neurological conditions such as cerebral ischemia.
EP05848068A 2004-11-08 2005-11-08 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death Withdrawn EP1811838A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62605404P 2004-11-08 2004-11-08
US63602404P 2004-12-13 2004-12-13
PCT/US2005/040360 WO2006052926A2 (en) 2004-11-08 2005-11-08 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death

Publications (2)

Publication Number Publication Date
EP1811838A2 EP1811838A2 (en) 2007-08-01
EP1811838A4 true EP1811838A4 (en) 2009-07-22

Family

ID=36337123

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05848068A Withdrawn EP1811838A4 (en) 2004-11-08 2005-11-08 Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death

Country Status (3)

Country Link
EP (1) EP1811838A4 (en)
CA (1) CA2587018A1 (en)
WO (1) WO2006052926A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0007556A (en) 1999-01-15 2001-10-23 Biogen Inc Tweak and tweak receptor antagonists and their use to treat immune disorders
CN103536916B (en) 2002-04-09 2016-08-17 比奥根Ma公司 For the method treating TWEAK associated conditions
EP1859277A4 (en) 2005-02-17 2010-03-17 Biogen Idec Inc Treating neurological disorders
EP1853312B1 (en) * 2005-03-07 2014-12-10 Genentech, Inc. Methods and compositions for modulating tweak and fn14 activity
JP5339901B2 (en) 2005-05-10 2013-11-13 バイオジェン・アイデック・エムエイ・インコーポレイテッド Treatment and evaluation of inflammatory injury
EA018255B1 (en) 2005-05-27 2013-06-28 Байоджен Айдек Ма Инк. Tweak binding proteins and use thereof
WO2006138219A2 (en) 2005-06-13 2006-12-28 Biogen Idec Ma Inc. Methods of diagnosis / prognosis of inflammatory conditions
US8093006B2 (en) 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
PE20131411A1 (en) 2010-10-05 2013-12-16 Hoffmann La Roche ANTIBODIES AGAINST HUMAN TWEAK AND USES OF THEM
JP6007310B2 (en) 2012-04-05 2016-10-12 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Bispecific antibodies against human TWEAK and human IL17 and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042073A1 (en) * 1999-01-15 2000-07-20 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000042073A1 (en) * 1999-01-15 2000-07-20 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
WO2006130374A2 (en) * 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Tweak binding antibodies

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
POTROVITA I ET AL: "TUMOR NECROSIS FACTOR-LIKE WEAK INDUCER OF APOPTOSIS-INDUCED NEURODEGENERATION", JOURNAL OF NEUROSCIENCE, NEW YORK, NY, US, vol. 24, no. 38, 22 September 2004 (2004-09-22), pages 8237 - 8244, XP009045900, ISSN: 0270-6474 *
POTROVITA I ET AL: "TWEAK - A REGULATOR OF NEURONAL CELL DEATH", NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, SPRINGER, BERLIN, DE, vol. 369, no. SUPPL. 01, 9 March 2004 (2004-03-09), pages R12, XP009045913, ISSN: 0028-1298 *
YEPES M ET AL: "A SOLUBLE FN14-FC DECOY RECEPTOR REDUCES INFARCT VOLUME IN A MURINE MODEL OF CEREBRAL ISCHEMIA", AMERICAN JOURNAL OF PATHOLOGY, AMERICAN SOCIETY FOR INVESTIGATIVE PATHOLOGY, US, vol. 166, no. 2, 1 February 2005 (2005-02-01), pages 511 - 520, XP009045901, ISSN: 0002-9440 *

Also Published As

Publication number Publication date
WO2006052926A2 (en) 2006-05-18
EP1811838A2 (en) 2007-08-01
CA2587018A1 (en) 2006-05-18
WO2006052926A3 (en) 2006-08-03

Similar Documents

Publication Publication Date Title
EP1811838A4 (en) Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
HRP20090195T1 (en) Mitotic kinesin inhibitors
IL165624A0 (en) Mitotic kinesin inhibitors
TW200833341A (en) 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions
GT200800265A (en) PIRIDO (3,2-E) PIRACINAS, ITS USE AS PHOSPHADESTERASE 10 INHIBITORS, AND PROCESSES TO PREPARE THEM.
MX2007014616A (en) Inhibitors of vegf receptor and hgf receptor signaling.
BRPI0517418A (en) compound, pharmaceutical composition, and methods for antagonizing cgrp receptor activity in a mammal to treat, control, ameliorate or reduce the risk of headache, migraine or headache, and treating or preventing migraine headaches. , headaches, and headaches
HK1130011A1 (en) Simultaneous, separate or sequential therapeutic use of at least one botulinum neurotoxin and of at least one opiate derivative
SI1896421T1 (en) Benzocycloheptapyridines as inhibitors of the receptor tyrosine kinase met
MX2009013321A (en) Spiro [piperidine-4, 4' -thieno [3, 2-c] pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis.
EP1551812A4 (en) Mitotic kinesin inhibitors
EP1481077A4 (en) Mitotic kinesin inhibitors
WO2005017190A3 (en) Mitotic kinesin inhibitors
EP1515949A4 (en) Mitotic kinesin inhibitors
WO2005018547A3 (en) Mitotic kinesin inhibitors
TW200510380A (en) Mitotic kinesin inhibitors
WO2007124308A3 (en) Methods and compositions for modulation of blood-neural barrier
DE60210067D1 (en) Tricyclische diazepine als tocolytische oxytocin rezeptor antagonisten
WO2004058148A3 (en) Mitotic kinesin inhibitors
WO2004058700A3 (en) Mitotic kinesin inhibitors
WO2006086358A3 (en) Mitotic kinesin inhibitors
WO2006078574A3 (en) Mitotic kinesin inhibitors
BR0014166A (en) Method of using rapid attack selective serotonin reabsorption inhibitors to treat sexual dysfunction
WO2004110380A3 (en) Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
PL1732926T3 (en) Mitotic kinesin inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070515

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

A4 Supplementary search report drawn up and despatched

Effective date: 20090618

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20090907